Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2013) 32 P190 | DOI: 10.1530/endoabs.32.P190

83 views


1Hospital Universitario Ramon y Cajal, Madrid, Spain; 2Universidad de Alcalá, Madrid, Spain; 3Hospital Comarcal de Melilla, Melilla, Spain; 4Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain; 5Universidad Autonoma, Madrid, Spain.


Introduction: Different studies have published that testosterone therapy in men and women results in decreased HDL cholesterol and increased LDL cholesterol, and therefore an increased cardiovascular risk.

Aims: To determine whether testosterone therapy has this effect on lipid parameters and markers of metabolic syndrome (MetSyn) in female-to-male transsexuals (FMT).

Material and methods: We studied 50 FMT, aged 27.8±7.6 years, at baseline and after 3 years of treatment with testosterone undecanoate (1000 mg/12 weeks, i.m.). None had done gonadectomy. Weight (W), BMI, waist and hip circumference, and systolic and diastolic blood pressure were determined. We also measured plasma levels of glucose, total cholesterol (TC), LDL, HDL, tryglicerides, apolipoprotein A-I (ApoA-I), apolipoprotein B (ApoB), lipoprotein (a) (Lp(a)), homocysteine (Hcy), 25-hydroxy vitamin D3, iron, ferritin, transferrin, total testosterone, estradiol, prolactin, sex hormone-binding globulin, delta 4-androstenedione, dehydroepiandrosterone sulphate, FSH and LH.

Results: After 3-year testosterone-therapy, there was a significant increase in the levels of testosterone (52±26–697±277 ng/dl, P=0.001), TC (166±29–180±33 mg/dl, P=0.031), LDL (97±27–113±27 mg/dl, P=0.027), ApoB (79±20–86±20 mg/dl, P=0.021), iron (74±38–96±47 mg/dl, P=0.031), ferritin (44±25–57±32 mg/dl, P=0.031), and Hcy (10±4–12±3 mg/dl, P=0.012); and a significant decrease of HDL (53±12–47±11 mg/dl, P=0.002), ApoA-I (152±25–135±23 mg/dl, P=0.001), and Lp(a) (24±20–18±20 mg/dl, P=0.041). The other values unchanged significantly.

Conclusion: We conclude that long-term testosterone-therapy in FMT can promote an increased atherogenic by lowering HDL and ApoA-I, and by increasing TC, LDL, ApoB, Hcy, iron, and ferritin levels. But on the other hand, it produces a decrease in Lp(a) and without changing other markers of MetSyn.

Article tools

My recent searches

No recent searches.